Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE-1: Mirikizumab in Pediatric UC
NCT04004611Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2020
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label trial of mirikizumab in ulcerative colitis (UC), sponsored by Eli Lilly and Company. Primary endpoint: Clearance of Mirikizumab at Week 52. Started May 2020; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04004611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004611.